Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration

BMC Medical Genetics

Zahurin Mohamed¹  Sharmilla Kanagasundram³  Nor Zuraida Zainal³  Gavin P Reynolds²  Suffee Nusrat Jahan³  Mohd Aizat Zain⁴ 

[1] The Pharmacogenomics Laboratory, Department of Pharmacology, University of Malaya, 50603, Kuala Lumpur, Malaysia;Biomedical Research Centre, Sheffield Hallam University, City Campus, Howard Street, Sheffield, S11WB, UK;Department of Psychological Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia;Department of Pharmacology, Department of Psychology Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia

关键词: Olanzapine;    Leukocytes;    Manic;    Bipolar disorder;   

Others  :  1177791
DOI  :  10.1186/1471-2350-13-91

 received in 2012-06-22, accepted in 2012-09-28,  发布年份 2012

【 摘 要 】

Background

One of the genes suggested to play an important role in the pathophysiology of bipolar disorder (BPD) is PDLIM5, which encodes LIM domain protein. Our main objective was to examine the effect of olanzapine treatment on PDLIM5 mRNA expression in the peripheral blood leukocytes of BPD patients.

Methods

We measured the expression of PDLIM5 mRNA from 16 patients with BPD Type I after 0, 4, and 8 weeks of treatment with olanzapine using quantitative real-time PCR. The Young Mania Rating Scale was used to evaluate the severity of manic symptoms in BPD patients. We also compared PDLIM5 mRNA expression in treatment-naïve BPD patients with that in healthy control subjects.

Results

No significant difference was found in PDLIM5 mRNA expression between patients before olanzapine treatment and following 4 and 8 weeks of treatment (p>0.05). Although we observed a significant reduction in the severity of manic symptoms in all BPD patients (p<0.05), the effectiveness of the medication did not significantly correlate with the expression of PDLIM5 mRNA (p>0.05). Interestingly, PDLIM5 mRNA expression differed significantly between treatment-naïve BPD patients and healthy control subjects (p=0.002).

Conclusion

PDLIM5 mRNA expression did not appear to be a reflection of the efficacy of olanzapine in reducing the manic symptoms of BPD. The significant difference in expression of PDLIM5 mRNA in the peripheral blood leukocytes of treatment-naïve BPD patients versus that of healthy control subjects, however, suggests that it may be a good biological marker for BPD.

【 授权许可】

   
2012 Zain et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]van Loo KM, Martens GJ: Genetic and environmental factors in complex neurodevelopmental disorders. Curr Genomics 2007, 8(7):429-444.
• [2]Kato T: Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007, 61(1):3-19.
• [3]Maeno-Hikichi Y, Chang S, Matsumura K, Lai M, Lin H, Nakagawa N, Kuroda S, Zhang JF: A PKC epsilon-ENH-channel complex specifically modulates N-type Ca2+ channels. Nat Neurosci 2003, 6(5):468-475.
• [4]Kuroda S, Tokunaga C, Kiyohara Y, Higuchi O, Konishi H, Mizuno K, Gill GN, Kikkawa U: Protein-protein interaction of zinc finger LIM domains with protein kinase C. J Biol Chem 1996, 271(49):31029-31032.
• [5]National Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/ webcite
• [6]Kato T, Iwayama Y, Kakiuchi C, Iwamoto K, Yamada K, Minabe Y, Nakamura K, Mori N, Fujii K, Nanko S, et al.: Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia. Mol Psychiatry 2005, 10(11):1045-1055.
• [7]Zhao T, Liu Y, Wang P, Li S, Zhou D, Zhang D, Chen Z, Wang T, Xu H, Feng G, et al.: Positive association between the PDLIM5 gene and bipolar disorder in the Chinese Han population. J Psychiatry Neurosci 2009, 34(3):199-204.
• [8]Horiuchi Y, Arai M, Niizato K, Iritani S, Noguchi E, Ohtsuki T, Koga M, Kato T, Itokawa M, Arinami T: A polymorphism in the PDLIM5 gene associated with gene expression and schizophrenia. Biol Psychiatry 2006, 59(5):434-439.
• [9]Liu Z, Liu W, Xiao Z, Wang G, Yin S, Zhu F, Wang H, Cheng J, Wang X, He X, et al.: A major single nucleotide polymorphism of the PDLIM5 gene associated with recurrent major depressive disorder. J Psychiatry Neurosci 2008, 33(1):43-46.
• [10]Squassina A, Manchia M, Manconi F, Piccardi M, Ardau R, Chillotti C, Severino G, Del Zompo M: A case–control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatr Genet 2008, 18(3):128-132.
• [11]Shi J, Badner JA, Liu C: PDLIM5 and susceptibility to bipolar disorder: a family-based association study and meta-analysis. Psychiatr Genet 2008, 18(3):116-121.
• [12]Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, Takeda M, Kunugi H, Itakura M, Ohmori T: Gene expression in the peripheral leukocytes and association analysis of PDLIM5 gene in schizophrenia. Neurosci Lett 2007, 415(1):28-33.
• [13]Iga J, Ueno S, Yamauchi K, Numata S, Motoki I, Tayoshi S, Kinouchi S, Ohta K, Song H, Morita K, et al.: Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett 2006, 400(3):203-207.
• [14]Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T: Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004, 9(4):406-416.
• [15]Iwamoto K, Bundo M, Washizuka S, Kakiuchi C, Kato T: Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. J Hum Genet 2004, 49(5):227-231.
• [16]Hahn CG, Friedman E: Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1999, 1(2):81-86.
• [17]Pandey GN, Ren X, Dwivedi Y, Pavuluri MN: Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. J Psychiatr Res 2008, 42(2):106-116.
• [18]Maturana AD, Nakagawa N, Yoshimoto N, Tatematsu K, Hoshijima M, Tanizawa K, Kuroda S: LIM domains regulate protein kinase C activity: a novel molecular function. Cell Signal 2011, 23(5):928-934.
• [19]Herrick S, Evers DM, Lee JY, Udagawa N, Pak DT: Postsynaptic PDLIM5/Enigma Homolog binds SPAR and causes dendritic spine shrinkage. Mol Cell Neurosci 2010, 43(2):188-200.
• [20]Squassina A, Congiu D, Manconi F, Manchia M, Chillotti C, Lampus S, Severino G, Zompo MD: The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacol Res 2008, 57(5):369-373.
• [21]Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011, 378(9799):1306-1315.
• [22]Moreno RA, Moreno DH, Soares MB, Ratzke R: [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. Rev Bras Psiquiatr 2004, 26(Suppl 3):37-43.
• [23]Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al.: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000, 57(9):841-849.
• [24]Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002, 59(1):62-69.
• [25]Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L: [Antipsychotics in bipolar disorders]. Encephale 2004, 30(5):417-424.
• [26]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33. quiz 34–57
• [27]Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15(2):97-98.
• [28]Court MH: Court lab- HW calculator. 2005. http://www.tufts.edu/~mcourt01/Documents/Court%20lab%20-%20HW%20calculator.xls webcite
• [29]Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, Bradman N, Goldstein DB: Population genetic structure of variable drug response. Nat Genet 2001, 29(3):265-269.
• [30]Reynolds GP: Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine. Therapeutic Advances in Psychopharmacology 2011, 1(6):197-204.
• [31]Schloesser RJ, Huang J, Klein PS, Manji HK: Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33(1):110-133.
• [32]Singh RK, Shi J, Zemaitaitis BW, Muma NA: Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther 2007, 322(1):133-140.
• [33]Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, et al.: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002, 159(6):1011-1017.
• [34]Mehta D, Menke A, Binder EB: Gene expression studies in major depression. Curr Psychiatry Rep 2010, 12(2):135-144.